Delivery Order SPE2DB22D2206-SPE2DB25FJC79
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,594.39 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract requires performance at AmerisourceBergen's Conshohocken, Pennsylvania location. Pulmozyme is a recombinant human deoxyribonuclease used primarily in the treatment of cystic fibrosis, reflecting the Defense Logistics Agency's ongoing...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) at a ceiling value of $6,286.98. This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor. The performance location is...
- The Defense Logistics Agency (DLA) awarded a $48,488.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units). The contract, which was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a $9.68K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on July 23, 2025, with completion expected by July 24, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M vehicle extending through...
- This is a $37,471.65 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Pulmozyme 1 mg/ml ampule, a medication used in the treatment of cystic fibrosis. The order has an ultimate completion date of August 30, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at...
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order valued at approximately $7,100 to Amerisourcebergen Drug Corporation for the supply of 4561860956 Pulmozyme 1 MG/ML ampules. The delivery order, issued under an unspecified governmentwide acquisition contract, calls for Amerisourcebergen to deliver 2.5mL ampules of the respiratory drug Pulmozyme to a location in Conshohocken, Pennsylvania by August 21, 2023. No subcontractors or set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5ml units) with a ceiling value of $3,644.71 under a firm fixed-price contract. This delivery order represents a non-set-aside competitive award and is child to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $2,583.60 delivery order to AmerisourceBergen Drug Corp for PULMOZYME 1 mg/ml ampules (2.5 ml units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with the Defense...
- This is a $27,880.43 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has an ultimate completion date of September 20, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,348.64 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in respiratory treatment. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC79Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $30,166.02 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Pulmozyme is a prescribed medication used primarily in the treatment of cystic fibrosis, reflecting the Defense Logistics Agency's critical role in ensuring military and federal healthcare systems have access to specialized pharmaceutical products. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The parent contract encompasses specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities across multiple therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.2k | 7/28/25 |